Treatment options for extended-spectrum beta-lactamase (ESBL) and AmpC-producing bacteria

References

• Harris PNA, Tambyah PA, Paterson DL. β-lactam and β-lactamase inhibitor combinations in the treatment of extended-spectrum β-lactamase producing Enterobacteriaceae: time for a reappraisal in the era of few antibiotic options? Lancet Infect Dis. 2015 Apr;15(4):475–485.
   PubMed Web of Science ®Google Scholar
• Harris P. Clinical management of infections caused by Enterobacteriaceae that express extended-spectrum β-lactamase and AmpC enzymes. Semin Respir Crit Care Med. 2015 Feb 2;36(01):056–73.
   Google Scholar
• Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis. 2008 Jan 15;46(2):155–164.
   PubMed Web of Science ®Google Scholar
• Prakash V, Lewis JS, Herrera ML, et al. Oral and parenteral therapeutic options for outpatient urinary infections caused by Enterobacteriaceae producing CTX-M extended-spectrum -lactamases. Antimicrob Agents Chemother. 2009 Mar 1;53(3):1278–1280.
   PubMed Web of Science ®Google Scholar
• Doddaiah V, Anjaneya D. Prevalence of ESBL, AmpC and Carbapenemase among gram negative bacilli isolated from clinical specimens. Am J Life Sci. 2014;2(2):76.
   Google Scholar
• Paterson DL, Bonomo RA. Extended-spectrum -lactamases: a clinical update. Clin Microbiol Rev. 2005 Oct 1;18(4):657–686.
   PubMed Web of Science ®Google Scholar
• Pitout JD, Laupland KB. Extended-spectrum β-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis. 2008;8(3):159–166.
   PubMed Web of Science ®Google Scholar
• Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev. 2001 Oct;14(4):933–951.
   PubMed Web of Science ®Google Scholar
• Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009 Jan 1;22(1):161–182.
   PubMed Web of Science ®Google Scholar
• Grover N, Sahni AK, Bhattacharya S. Therapeutic challenges of ESBLS and AmpC beta-lactamase producers in a tertiary care center. Med J Armed Forces India. 2013 Jan;69(1):4–10.
   PubMedGoogle Scholar
• Oberoi L, Singh N, Sharma P, et al. ESBL, MBL and Ampc lactamases producing superbugs – havoc in the intensive care units of Punjab India. J Clin Diagn Res [Internet]. 2013 ;7(1).[cited 2015 Jul 18].
   Google Scholar
• Collins VL, Marchaim D, Pogue JM, et al. Efficacy of ertapenem for treatment of bloodstream infections caused by extended-spectrum-β-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2012 Apr;56(4):2173–2177.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Han JH, Rock C, et al. Carbapenem therapy is associated with improved survival compared with Piperacillin-Tazobactam for patients with extended-spectrum -lactamase bacteremia. Clin Infect Dis [Internet]. 2015 May 1;60(9). [cited 2015 Jul 6].
   Web of Science ®Google Scholar
• Vardakas KZ, Tansarli GS, Rafailidis PI, et al. Carbapenems versus alternative antibiotics for the treatment of bacteraemia due to Enterobacteriaceae producing extended-spectrum -lactamases: a systematic review and meta-analysis. J Antimicrob Chemother. 2012 Dec 1;67(12):2793–2803.
   PubMed Web of Science ®Google Scholar
• Armand-Lefevre L, Angebault C, Barbier F, et al. Emergence of imipenem-resistant gram-negative bacilli in intestinal flora of intensive care patients. Antimicrob Agents Chemother. 2013 Mar 1;57(3):1488–1495.
   PubMed Web of Science ®Google Scholar
• Chang HJ, Hsu PC, Yang CC, et al. Risk factors and outcomes of carbapenem-nonsusceptible Escherichia coli bacteremia: a matched case–control study. J Microbiol Immunol Infect. 2011 Apr;44(2):125–130.
   PubMedGoogle Scholar
• Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010 Mar 1;54(3):969–976.
   PubMed Web of Science ®Google Scholar
• Thomson KS, Moland ES. Cefepime, Piperacillin-Tazobactam, and the inoculum effect in tests with extended-spectrum beta-lactamase-producing Enterobacteriaceae. Antimicrob Agents Chemother. 2001 Dec 1;45(12):3548–3554.
   PubMed Web of Science ®Google Scholar
• Thomson KS. Extended-spectrum- beta-lactamase, AmpC, and Carbapenemase issues. J Clin Microbiol. 2010 Apr 1;48(4):1019–1025.
   PubMed Web of Science ®Google Scholar
• Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)-producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs. 2003;63(4):353–365.
   PubMed Web of Science ®Google Scholar
• Weber DA, Sanders CC. Diverse potential of beta-lactamase inhibitors to induce class I enzymes. Antimicrob Agents Chemother. 1990 Jan;34(1):156–158.
   PubMed Web of Science ®Google Scholar
• Martínez-Martínez L, Pascual A, Hernández-Allés S, et al. Roles of beta-lactamases and porins in activities of carbapenems and cephalosporins against Klebsiella pneumoniae. Antimicrob Agents Chemother. 1999 Jul;43(7):1669–1673.
   PubMed Web of Science ®Google Scholar
• James CE, Mahendran KR, Molitor A, et al. How β-lactam antibiotics enter bacteria: a dialogue with the Porins. Fatouros D, editor. PLoS One. 2009 May 12;4(5):e5453.
   PubMed Web of Science ®Google Scholar
• Bryan LE, editor. Microbial resistance to drugs [Internet]. Berlin, Heidelberg: Springer; 1989 [cited 2015 Jul 18].
   Google Scholar
• Macdougall C. Beyond susceptible and resistant, part I: treatment of infections due to Gram-negative organisms with inducible β-lactamases. J Pediatr Pharmacol Ther. 2011 Jan;16(1):23–30.
   PubMedGoogle Scholar
• Ramphal R. Extended-spectrum -lactamases and clinical outcomes: current data. Clin Infect Dis. 2006 Apr 15;42(Supplement 4):S164–S172.
   Google Scholar
• Gavin PJ, Suseno MT, Thomson RB, et al. Clinical correlation of the CLSI susceptibility breakpoint for piperacillin- tazobactam against extended-spectrum-beta-lactamase-producing Escherichia coli and Klebsiella species. Antimicrob Agents Chemother. 2006 Jun;50(6):2244–2247.
   PubMed Web of Science ®Google Scholar
• Trivedi M, Patel V, Soman R, et al. The outcome of treating ESBL infections with carbapenems vs. non carbapenem antimicrobials. J Assoc Physicians India. 2012;60:28–30.
   PubMedGoogle Scholar
• Rodríguez-Baño J, Alcalá JC, Cisneros JM, et al. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Arch Intern Med. 2008 Sep 22;168(17):1897–1902.
   PubMedGoogle Scholar
• Park SH, Choi SM, Chang YK, et al. The efficacy of non-carbapenem antibiotics for the treatment of community-onset acute pyelonephritis due to extended-spectrum -lactamase-producing Escherichia coli. J Antimicrob Chemother. 2014 Oct 1;69(10):2848–2856.
   PubMed Web of Science ®Google Scholar
• Ofer-Friedman H, Shefler C, Sharma S, et al. Carbapenems versus Piperacillin-Tazobactam for bloodstream infections of nonurinary source caused by extended-spectrum beta-lactamase–producing Enterobacteriaceae. Infect Control Hosp Epidemiol. 2015 May 20;36(8):1–5.
   PubMedGoogle Scholar
• Kang CI, Park SY, Chung DR, et al. Piperacillin-tazobactam as an initial empirical therapy of bacteremia caused by extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae. J Infect. 2012 May;64(5):533–534.
   PubMed Web of Science ®Google Scholar
• Chopra T, Marchaim D, Veltman J, et al., et al. Impact of cefepime therapy on mortality among patients with bloodstream infections caused by extended-spectrum- -lactamase-producing Klebsiella pneumoniae and Escherichia coli. Antimicrob Agents Chemother. 2012 Jul 1;56(7):3936–3942.
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Sanguinetti M, Montuori E, et al. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum- -lactamase-producing enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob Agents Chemother. 2007 Jun 1;51(6):1987–1994.
   PubMed Web of Science ®Google Scholar
• Retamar P, López-Cerero L, Muniain MA, et al. Impact of the MIC of piperacillin-tazobactam on the outcome of patients with bacteremia due to extended-spectrum-β-lactamase-producing Escherichia coli. Antimicrob Agents Chemother. 2013 Jul;57(7):3402–3404.
   PubMed Web of Science ®Google Scholar
• Hyle EP, Lipworth AD, Zaoutis TE, et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing enterobacteriaceae: variability by site of infection. Arch Intern Med. 2005 Jun 27;165(12):1375–1380.
   PubMedGoogle Scholar
• Clinical and Laboratory Standards Institute, editor. Performance standards for antimicrobial disk susceptibility test: twenty-fifth informational supplement. Wayne, PA: Committee for Clinical Laboratory Standards; 2015. p. 236.
   Google Scholar
• Lee NY, Lee CC, Huang WH, et al. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing enterobacteriaceae: MIC matters. Clin Infect Dis. 2013 Feb 15;56(4):488–495.
   PubMed Web of Science ®Google Scholar
• Mendes RE, Castanheira M, Gasink L, et al. Beta-lactamase characterization of Gram-negative pathogens recovered from patients enrolled in the phase 2 trials for ceftazidime-avibactam: clinical efficacies analyzed against subsets of molecularly characterized isolates. Antimicrob Agents Chemother. 2015. [Epub ahead of print].
   Google Scholar
• Labombardi VJ, Rojtman A, Tran K. Use of cefepime for the treatment of infections caused by extended spectrum beta-lactamase-producing Klebsiella pneumoniae and Escherichia coli. Diagn Microbiol Infect Dis. 2006 Nov;56(3):313–315.
   PubMed Web of Science ®Google Scholar
• Zanetti G, Bally F, Greub G, et al. Cefepime versus imipenem-cilastatin for treatment of nosocomial pneumonia in intensive care unit patients: a multicenter, evaluator-blind, prospective, randomized study. Antimicrob Agents Chemother. 2003 Nov;47(11):3442–3447.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Bano J, Navarro MD, Retamar P, et al. The extended-spectrum beta-lactamases-red Espanola de investigacion en patologia infecciosa/grupo de estudio de infeccion hospitalaria group. Beta-lactam/ beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum -lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin Infect Dis. 2012 Jan 15;54(2):167–174.
   PubMed Web of Science ®Google Scholar
• Perez F, Bonomo RA. Can we really use beta-lactam/beta-lactam inhibitor combinations for the treatment of infections caused by extended-spectrum ss-lactamase-producing bacteria? Clin Infect Dis. 2012 Jan 15;54(2):175–177.
   PubMed Web of Science ®Google Scholar
• Roos JF, Bulitta J, Lipman J, et al. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. J Antimicrob Chemother. 2006 Sep 6;58(5):987–993.
   PubMed Web of Science ®Google Scholar
• The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 5.0; 2015. [cited 2016 Jan 28]. Available from: http://www.eucast.org
   Google Scholar
• Matsumura Y, Yamamoto M, Nagao M, et al. Multicenter retrospective study of cefmetazole and flomoxef for treatment of extended-spectrum-beta-lactamase-producing Escherichia coli bacteremia. Antimicrob Agents Chemother. 2015 Sep;59(9):5107–5113.
   PubMed Web of Science ®Google Scholar
• Blanchette LM, Kuti JL, Nicolau DP, et al. Clinical comparison of ertapenem and cefepime for treatment of infections caused by AmpC beta-lactamase-producing Enterobacteriaceae. Scand J Infect Dis. 2014 Nov;46(11):803–808.
   PubMed Web of Science ®Google Scholar
• Tamma PD, Girdwood SCT, Gopaul R, et al. The use of cefepime for treating AmpC beta-lactamase-producing Enterobacteriaceae. Clin Infect Dis. 2013 Sep 15;57(6):781–788.
   PubMed Web of Science ®Google Scholar
• Siedner MJ, Galar A, Guzman-Suarez BB, et al. Cefepime vs other antibacterial agents for the treatment of Enterobacter species bacteremia. Clin Infect Dis. 2014 Jun 1;58(11):1554–1563.
   PubMed Web of Science ®Google Scholar
• Harris PNA, Wei JY, Shen AW, et al. Carbapenem versus alternative antibiotics for the treatment of bloodstream infections caused by Enterobacter, Citrobacter or Serratia species: a systematic review with meta-analysis. J Antimicrob Chemother. 2016;71:296–306.
   PubMed Web of Science ®Google Scholar
• Lee NY, Lee CC, Li CW, et al. Cefepime therapy for monomicrobial enterobacter cloacae bacteremia: unfavorable outcome in patients infected by cefepime susceptible-dose dependent isolates. Antimicrob Agents Chemother. 2015 Sep 28;59(12). [Epub ahead of print].
   Web of Science ®Google Scholar
• Altshuler J, Aitken SL, Guervil D, et al. Treatment of extended-spectrum beta-lactamase enterobacteriaceae with cefepime: the dose matters, too. Clin Infect Dis. 2013;57(6):915–916.
   PubMed Web of Science ®Google Scholar
• Griffith MM, Gross AE, Sutton SH, et al. The impact of anti-infective drug shortages on hospitals in the united states: trends and causes. Clin Infect Dis. 2012 Jan;54(5):684–691.
   PubMed Web of Science ®Google Scholar
• Harris P, Peleg AY, Iredell J, et al. Meropenem versus piperacillin-tazobactam for definitive treatment of bloodstream infections due to ceftriaxone non-susceptible Escherichia coli and Klebsiella spp (the MERINO trial): study protocol for a randomised controlled trial. Trials. 2015;16(1):24.
   PubMed Web of Science ®Google Scholar
• Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015 Sep;46(3):266–271.
   PubMed Web of Science ®Google Scholar